AB Klaipėdos nafta (KN) will hold an Investor Conference Webinar to introduce unaudited financial results for the nine months of 2019


KN invites shareholders, investors, analysts and other stakeholders to join its investor conference webinar scheduled on the October 30th of 2019 at 8.30 am (EET). The presentation will be held in English.

The webinar will be hosted by Company’s management who will introduce the performance and unaudited financial results of KN for the nine months of 2019.

After the presentation investors are welcome to ask questions. Due to limited webinar time, we encourage participants to send their questions before the webinar until October 28th to

How to join the webinar?

To join the webinar, please register via following link: You will be provided with the webinar link and instructions how to join successfully. When joining the webinar for the first time, you will be asked to download the plug-in which will take only few seconds. In case plug-in can't be downloaded, a web browser which enables attending the webinar, opens automatically. The webinar will be recorded and available online for everyone at the company’s website on and on Nasdaq Baltic account.

What is a corporate webinar?

A corporate webinar is a virtual conference, during which company’s representatives provide information about the company and its performance. Webinar allows interactive communication and a possibility to ask questions and get answers directly from the company while being located anywhere.       

Jonas Lenkšas, Chief Financial Officer, +370 694 80594 


About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Auriant Mining AB (publ.) publishes January-March 2020 Interim Report29.5.2020 08:00:00 CESTPress release

Highlights • Gold production for Q1 2020 was 278 kg (8,946 oz), an increase of 223% compared to 86 kg (2,773 oz) in Q1 2019. • Volume of ore processed through the newly built CIL plant amounted to 100 thousand tonnes with an average grade of 3.04 g/t (total gold in processed ore – 303 kg). Over the ramp up period, the Company reached projected throughput per working hour (50 t/hour) and recovery rate (>90%). • Q1 2020 gold sales amounted to 317 kg (10,193 oz), compared to 98 kg (3,157 oz) in Q1 2019, an increase of 219 kg (7,036 oz). • Consolidated revenue was MSEK 156.2 (US$ 16.2 mln), up 290% YoY (Q1 2019: MSEK 38.0 (US$ 4.1 mln)). • Net profit after tax amounted to MSEK 56.1 (US$ 5.9 mln) compared to loss of MSEK -14.2 (US$ -1.6 mln) in Q1 2019. • Strong increase in EBITDA: in Q1 2020 EBITDA amounted to MSEK 92.4 (US$ 9.5 mln) compared to MSEK 2.1 (US$ 0.2 mln) in the previous year. • Net cash flow from operating activities was MSEK 76.8 (US$ 7.9 mln), up 1463% YoY (Q1 2019: MSEK 4.

Better Collective – Share buyback program29.5.2020 08:00:00 CESTPress release

Regulatory Release 26/2020 On March 19, 2020 Better Collective A/S initiated a share buyback program for up to EUR 5,000,000 (SEK 54,580,500), to be executed during the period from March 19, 2020 to June 30, 2020. The following transactions have been executed under the program during the period from May 22, 2020 to May 28, 2020: Date Number of sharesAverage weighted purchase price (SEK per share)Amount (SEK)Accumulated under the program as of last announcement:499,18677.750238,811,788.1322/05/20204,43891.2765405,085.1125/05/20206,00090.7015544,209.0026/05/20204,81890.7525437,245.5527/05/20206,00091.5859549,515.4028/05/20203,34791.5477306,410.15Accumulated under the program following above purchases:523,78978.379441,054,253.34 Following the above purchases, Better Collective A/S holds 523,789 treasury shares corresponding to 1.12 % of the outstanding share capital of the company Purchases for an amount of up to EUR 1,239,110 (SEK 13,526,247) remain to be executed under the program. Cont

Auriant Mining AB publicerar sin delårsrapport för perioden 1 januari - 31 mars 202029.5.2020 08:00:00 CESTPressemelding

Viktiga händelser Guldproduktionen i Q1 2020 var 278 kg (8 946 oz), en ökning med 223% jämfört med 86 kg (2 773 oz) under Q1 2019. Volymen av malm som bearbetats genom den nybyggda CIL-anläggningen uppgick till 100 kt med en snitthalt om 3,04 g/t (totalt guld i malmen - 303 kg). Under upptrappningsperioden nådde Bolaget beräknad bearbetningskapacitet per arbetstimme (50 ton/timme) och återvinningsgrad (> 90%). Guldförsäljning under Q1 2020 uppgick till 317 kg (10 193 oz), jämfört med 98 kg (3 157 oz) under Q1 2019, en ökning med 219 kg (7 036 oz). Konsoliderade intäkter var 156,2 MSEK (16,2 MUSD), en ökning med 290% på årsbasis (under Q1 2019: 38,0 MSEK (4,1 MUSD)). Nettovinst efter skatt uppgick till 56,1 MSEK (5,9 MUSD), jämfört med en förlust på -14,2 MSEK (-1,6 MUSD) under Q1 2019. En betydlig ökning av EBITDA: under Q1 2020 EBITDA uppgick till 92,4 MSEK (9,5 MUSD) jämfört med 2,1 MSEK (0,2 MUSD) under föregående år. Nettokassaflöde från den löpande verksamheten var 76,8 MSEK (7,9

Recording of the Latvijas Gaze 3 months 2020 Investor Conference Webinar29.5.2020 07:40:00 CESTPress release

On May 28 JSC “Latvijas Gāze” organized its Investor Conference Online Webinar. During the webinar the Vice-Chairman of Management Board Sebastian Groeblinghoff analyzed “Latvijas Gāze” Group’s unaudited financial results of 3 months 2020 and informed about other key initiatives of the Group. The recorded webinar is available online:, and the presentation, demonstrated during the webinar, is available in the attachment. Additional information: Madara Ventere Head of Finance and accounting division Phone: + (371) 67 369 281 E-mail: Attachment 2020-05-28_Latvijas Gaze Unaudited Q1 Results 2020_Investor_Webinar

Radisson Hospitality AB’s Q1 2020 Report29.5.2020 07:30:00 CESTPress release

January–March 2020 First Quarter 2020 Revenue decreased by MEUR 42.8 (–20.1%) to MEUR 170.6. The decrease is due to the negative impact of the COVID-19 outbreak. At the end of the quarter, 170 hotels were closed due to the pandemic. On a like-for-like basis, including hotels under renovation (“LFL&R”), Revenue decreased by MEUR 41.7 (–20.1%).Reported RevPAR for leased and managed hotels decreased by 20.7%. RevPAR LFL&R decreased by 20.1%.EBITDA decreased by MEUR 30.5 to MEUR –5.3. The results in March was severely impacted by the revenue drop due to COVID-19. The cost base was significantly reduced in the hotels as of March, while the full impact of the measures taken to reduce central costs is only visible as from April. The EBITDA margin was –3.1% (11.8%).EBIT decreased by MEUR 34.5 to MEUR –27.4. In addition to the EBITDA decrease, results are impacted by costs for depreciation on the new IT platform and investments in the leased properties in 2019. The EBIT margin was –16.1% (3.3%)

Updated data demonstrate Roche’s Alecensa increases overall survival rate for people with ALK-positive non-small cell lung cancer29.5.2020 07:00:00 CESTPress release

ALEX study is the first global phase III study to show a clinically meaningful benefit in overall survival at five years (62.5% with Alecensa), compared with crizotinib (45.5%)Data confirm longer-term efficacy of Alecensa, both in patients with or without central nervous system metastases at baseline Basel, 29 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented updated data from the pivotal phase III ALEX study, showing an increased five-year survival rate with Alecensa® (alectinib), compared with crizotinib, in people living with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). These data confirm the longer-term efficacy of Alecensa already demonstrated across three phase III clinical trials. Full findings were presented at the ASCO20 Virtual Scientific Programme, on 29 May 2020. “These data further support Alecensa as the standard of care for people with metastatic ALK-positive NSCLC,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Offic